Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation

Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation

- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases   - Lead asset Exl-111 builds on proven IgE biology with a differentiated mechanism designed to dissociate receptor-bound IgE and drive faster, deepe…

- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases- Lead asset Exl-111 builds on proven IgE biology with a differentiated mechanism designed… [+6821 chars]
Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation - FHMnews